2023
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals
2009
Intensive Care Unit Management of Status Asthmaticus
Marshall P, Possick J, Chupp G. Intensive Care Unit Management of Status Asthmaticus. Clinical Pulmonary Medicine 2009, 16: 293-301. DOI: 10.1097/cpm.0b013e3181bdff38.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSevere asthma exacerbationsNear-fatal asthmaStatus asthmaticusMechanical ventilationAsthma exacerbationsExtrinsic positive end-expiratory pressureIntensive care unit managementPositive end-expiratory pressureEmergency department visitsNoninvasive mechanical ventilationSubset of patientsEnd-expiratory pressureTypical risk factorsHigh-risk populationRisk of barotraumaUse of sedativesSevere exacerbationsICU admissionSevere asthmaPermissive hypercapniaSystemic therapyDepartment visitsHospital admissionExpiratory pressureRisk stratification